Search | Clinical Trials Finder

Conditions: Breast Cancer
Interventions: Anastrozole, AZD0530 (saracatinib), Placebo; Drug
Lead sponsor: Joyce Marie Slingerland, MD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2018
U.S. locations: 2
States / cities: Palo Alto, California • Miami, Florida

Conditions: Secondary Amenorrhea
Interventions: Progesterone, Placebo; Drug
Lead sponsor: TherapeuticsMD; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 22
States / cities: Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 19 more

Conditions: Hormone Regulation
Interventions: Beyond Hormone, Placebo; Dietary Supplement · Other
Lead sponsor: Scale Media Inc; Industry
Eligibility: 25 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Systemic Lupus Erythematosus
Interventions: Prednisone, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 13 Years to 65 Years · Female only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2003
U.S. locations: 3
States / cities: New Hyde Park, New York • New York, New York • The Bronx, New York

Conditions: Breast Cancer
Interventions: Palbociclib, Aromatase Inhibitor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 65 Years and older
Enrollment: 779 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer
Interventions: letrozole, MRI, conventional surgery; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older · Female only
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 32
States / cities: Los Angeles, California • Oakland, California • San Francisco, California + 22 more

Conditions: Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor Positive, HER2/Neu Negative, Metastatic Malignant Solid Neoplasm, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Recurrent Breast Carcinoma, TP53 wt Allele, Unresectable Malignant Solid Neoplasm
Interventions: MDM2/MDMX Inhibitor ALRN-6924, Paclitaxel; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Menopause
Interventions: esterified estrogens 1.25 mg and methyltestosterone 2.5 mg, Esterified estrogens 1.25 mg; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 78
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more

Conditions: Prostate, Cancer, Hormonal Cycling
Interventions: GnRH, Ketoconazole, Bicalutamide, Testosterone transdermal gel, Estrogen transdermal patch; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Obesity
Interventions: exercise; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Infertility, Diminished Ovarian Reserve, IVF
Interventions: Timing of injectable gonadotropins; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Infertility
Interventions: Oral contraceptive pill and microdose lupron, E2 patch/antagonist; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 50 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Vasomotor Symptoms Associated With Menopause
Interventions: Bazedoxifene/Conjugated Estrogen; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 40 Years to 64 Years · Female only
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 7
States / cities: Phoenix, Arizona • Fort Myers, Florida • North Port Richey, Florida + 4 more

Conditions: Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer, HER2 Negative Breast Carcinoma
Interventions: Palazestrant, Letrozole-matching placebo, Ribociclib, Letrozole, Palazestrant matching-placebo; Drug
Lead sponsor: Olema Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 47
States / cities: Hot Springs, Arkansas • Beverly Hills, California • La Jolla, California + 44 more

Conditions: Diabetes Mellitus, Type 1
Interventions: Antioxidant Cocktail, Resveratrol, Placebo; Dietary Supplement · Other
Lead sponsor: Augusta University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 143 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Augusta, Georgia

Conditions: Healthy Volunteers
Interventions: Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay, Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Menopause, Postmenopause
Interventions: Estrogen; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atrophic Vaginitis
Interventions: Estriol, Estradiol valerate, Vanicream Lite; Drug
Lead sponsor: Maire Mac Bride; Other
Eligibility: 40 Years to 75 Years · Female only
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Breast Neoplasms
Interventions: PD0332991, Anastrozole, Goserelin, Surgery (standard of care), Tumor biopsy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 4
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Rochester, Minnesota + 1 more

Conditions: Hormone Replacement Therapy
Interventions: Estradiol acetate, Estradiol, Conjugated equine estrogens; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 32
States / cities: Phoenix, Arizona • Carmichael, California • San Diego, California + 28 more

Conditions: Hemorrhagic Shock
Interventions: Premarin IV, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Transgender Persons
Interventions: Botnia Clamp, Withdrawal of Gender Affirming Hormone Therapy (GAHT); Drug · Other
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Vaginal Health
Interventions: estriol, Placebo; Drug
Lead sponsor: Gynuity Health Projects; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Los Angeles, California • Chicago, Illinois

Conditions: Breast Cancer
Interventions: Vagifem; Behavioral
Lead sponsor: Susan Tannenbaum; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Farmington, Connecticut

Search by objective public record fields.

A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding for Secondary Amenorrhea

A Clinical Trial to Examine the Efficacy of a Supplement to Support Hormone Regulation in Women

Serologically Active, Clinically Stable Systemic Lupus Erythematosus

Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

Women in Steady Exercise Research [Formerly Women, Oxidative Stress, Exercise and Estrogens (WOSEE)]

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

Oral Microdose Lupron Versus Luteal Estradiol Trial in Poor Responder In Vitro Fertilization (IVF) Patients

Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Estrogen and Diabetes

The Effect of an Adhesive Overlay on the Delivery of Contraceptive Hormones From ORTHO EVRA® in Healthy Women

Buccal Estrogen in Toothpaste Study: Systemic Absorption of Estradiol When Administered Mixed With Toothpaste in Postmenopausal or Surgically Menopausal Women

A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Hormone Replacement Therapy for Use in Postmenopausal Women for Relief of Hot Flushes and Urogenital Symptoms.

Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)

Effect of Gender Affirming Hormone Therapy on Glucose Metabolism

Topical Estriol for Vaginal Health

Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors